170 related articles for article (PubMed ID: 20147581)
21. Water fluoridation and osteoporotic fracture.
Hillier S; Inskip H; Coggon D; Cooper C
Community Dent Health; 1996 Sep; 13 Suppl 2():63-8. PubMed ID: 8897754
[TBL] [Abstract][Full Text] [Related]
22. [Recommendations of FRAX in clinical assessment of osteoporosis indicated in European and US guidelines].
Nakamura T
Clin Calcium; 2009 Dec; 19(12):1723-8. PubMed ID: 19949262
[TBL] [Abstract][Full Text] [Related]
23. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice.
Watts NB
J Womens Health (Larchmt); 2011 Apr; 20(4):525-31. PubMed ID: 21438699
[TBL] [Abstract][Full Text] [Related]
24. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.
Bliuc D; Nguyen ND; Milch VE; Nguyen TV; Eisman JA; Center JR
JAMA; 2009 Feb; 301(5):513-21. PubMed ID: 19190316
[TBL] [Abstract][Full Text] [Related]
25. Choice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic.
Thomsen K; Ryg J; Matzen L; Hermann AP; Masud T
Dan Med J; 2014 Dec; 61(12):A4980. PubMed ID: 25441734
[TBL] [Abstract][Full Text] [Related]
26. A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies.
Pluijm SM; Koes B; de Laet C; Van Schoor NM; Kuchuk NO; Rivadeneira F; Mackenbach JP; Lips P; Pols HA; Steyerberg EW
J Bone Miner Res; 2009 May; 24(5):768-74. PubMed ID: 19113932
[TBL] [Abstract][Full Text] [Related]
27. Impact of UK National Guidelines based on FRAX®--comparison with current clinical practice.
Crabtree NJ; Bebbington NA; Chapman DM; Wahid YS; Ayuk J; Boivin CM; Cooper MS; Gittoes NJ;
Clin Endocrinol (Oxf); 2010 Oct; 73(4):452-6. PubMed ID: 20626412
[TBL] [Abstract][Full Text] [Related]
28. The effect of osteoporotic treatment on the functional outcome, re-fracture rate, quality of life and mortality in patients with hip fractures: a prospective functional and clinical outcome study on 520 patients.
Makridis KG; Karachalios T; Kontogeorgakos VA; Badras LS; Malizos KN
Injury; 2015 Feb; 46(2):378-83. PubMed ID: 25541417
[TBL] [Abstract][Full Text] [Related]
29. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
30. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
31. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Siris ES; Baim S; Nattiv A
Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with 5-year risk of hip fracture in postmenopausal women.
Robbins J; Aragaki AK; Kooperberg C; Watts N; Wactawski-Wende J; Jackson RD; LeBoff MS; Lewis CE; Chen Z; Stefanick ML; Cauley J
JAMA; 2007 Nov; 298(20):2389-98. PubMed ID: 18042916
[TBL] [Abstract][Full Text] [Related]
33. Identification of osteopenic women at high risk of fracture: the OFELY study.
Sornay-Rendu E; Munoz F; Garnero P; Duboeuf F; Delmas PD
J Bone Miner Res; 2005 Oct; 20(10):1813-9. PubMed ID: 16160738
[TBL] [Abstract][Full Text] [Related]
34. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study.
Khaw KT; Reeve J; Luben R; Bingham S; Welch A; Wareham N; Oakes S; Day N
Lancet; 2004 Jan; 363(9404):197-202. PubMed ID: 14738792
[TBL] [Abstract][Full Text] [Related]
35. An audit of current clinical practice in the management of osteoporosis in Nottingham.
Sahota O; Worley A; Hosking DJ
J Public Health Med; 2000 Dec; 22(4):466-72. PubMed ID: 11192273
[TBL] [Abstract][Full Text] [Related]
36. Failure in the application of fragility fracture prevention guidelines.
Elvey MH; Pugh H; Schaller G; Dhotar G; Patel B; Oddy MJ
Ann R Coll Surg Engl; 2014 Jul; 96(5):381-5. PubMed ID: 24992424
[TBL] [Abstract][Full Text] [Related]
37. Management recommendations for osteoporosis in clinical guidelines.
Wang M; Bolland M; Grey A
Clin Endocrinol (Oxf); 2016 May; 84(5):687-92. PubMed ID: 26668071
[TBL] [Abstract][Full Text] [Related]
38. Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain.
Hurtado I; Sanfélix-Gimeno G; Baixauli-Pérez C; Peiró S; Sanfélix-Genovés J
J Clin Endocrinol Metab; 2014 Jan; 99(1):142-50. PubMed ID: 24384018
[TBL] [Abstract][Full Text] [Related]
39. Osteoporosis assessment and treatment in older patients who have sustained a hip fracture.
Lowdon DW; Quinn C; Mole P; Leese GP
Scott Med J; 2006 May; 51(2):32-5. PubMed ID: 16722136
[TBL] [Abstract][Full Text] [Related]
40. Managing osteoporosis with FRAX® in Australia: proposed new treatment thresholds from the 45&Up Study cohort.
Chen JS; Simpson JM; Blyth FM; March LM
Bone; 2014 Dec; 69():148-53. PubMed ID: 25263521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
